Adult Acute Lymphoblastic Leukemia: A Genetic Overview and Application to Clinical Practice

Jacobson, Stephanie; Tedder, Matthew L.; Eggert, Julie

doi:10.1188/16.cjon.e147-e154

Cited by 9 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we performed multivariate analysis to resolve these confounding factors. Studies have shown that the prognostic impact of traditional factors such as age and WBC count may be outweighed by that of cytogenetic and molecular features [4]. The prognostic value of IKZF1 deletion was not significant in this study, probably because there were only 28 patients with IKZF1 deletion, which was too few in each group to provide a significant prognostic value.…”

Section: Discussioncontrasting

confidence: 71%

“…Various factors have been identified in risk stratification, but many relapses occur in patients who initially present no known adverse risk features, suggesting the heterogeneous biological and clinical characteristics of adult B-ALL [3]. Therefore identifying novel prognostic biomarkers may be particularly helpful for patients yet unclassified by the known risk factors and may facilitate further refinement of risk stratification and risk-adapted therapy [4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia

Zhang

et al. 2020

Hematology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 71%

Section: Introductionmentioning

confidence: 99%

Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia

Zhang

et al. 2020

Hematology

View full text Add to dashboard Cite

“…Their clinical manifestations are anemia, bleeding, infection, infiltration, etc. [ 1 – 3 ] At present, the etiology is not completely clear, which may be related to viral infection, physical, and chemical factors, genetic quality, and so on. Its pathogenesis includes the transformation of the proto-oncogene, the aberration of anti-oncogene, inhibition of apoptosis, etc.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia

et al. 2020

View full text Add to dashboard Cite

Background: To systematic review the efficacy and safety of 6-thioguanine (6-TG) in the substitute of 6-mercaptopurine (6-MP) in the treatment for patients with childhood acute lymphoblastic leukemia (ALL) in the maintenance phase, and to explore its clinical application value. It provides theoretical guidance for the maintenance treatment of ALL in children from the perspective of evidence-based medicine. Methods: By means of computer retrieval, Chinese databases were searched: Chinese Biomedical Database (CBM), China national knowledge internet (CNKI), Chongqing Weipu Database (VIP), and Wanfang Database; Foreign databases: PubMed, The Cochrane Library, Embase, and Web of Science were applied to find out randomized controlled trial (RCT) for 6-TG in childhood acute lymphoblastic leukemia. By manual retrieval, documents without electronic edition and related conference papers were retrieved. The retrieval time ranges from the beginning of the establishment of the databases to September 1st, 2019. According to the inclusion, and exclusion criteria by 3 researchers, the literature screening, data extraction, and research methodological quality evaluation were completed. RevMan 5.3 software was applied to evaluate the quality of the included literature, and Stata 12.0 software was used to conduct meta-analysis of the outcome indicators of the included literature. Results: This study systematically evaluated the efficacy and safety of 6-TG in the substitute of 6-MP as a maintenance drug for childhood acute lymphoblastic leukemia. Through the key outcome indicators, this study is expected to draw a scientific, practical conclusion for 6-TG in the treatment of childhood acute lymphoblastic leukemia. This conclusion will provide evidence-based medical direction for clinical treatment. Conclusion: The efficacy and safety of 6-TG in the substitute of 6-MP in the maintenance treatment of childhood acute lymphoblastic leukemia will be confirmed through this study. The conclusions will be published in relevant academic journals. Registration: PROSPERO (registration number is CRD42020150466).

show abstract

“…ALL affects children as well as elderly individuals with a significantly different outcome. While children are reported to have a long-term survival probability of approximately 80% [ 1 , 2 ], in adults relapse-free survival is lower than 30% [ 3 ]. Patients showing mixed-lineage leukaemia ( MLL ) rearrangements display even lower survival rates [ 4 – 7 ].…”

Section: Introductionmentioning

confidence: 99%

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Sklarz¹,

Gladbach²,

Ernst³

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often lacking, the identification of combinationinduced molecular mechanisms bears significant value for the further development of interventional approaches. Methods: Combined application of conventional cytostatic agents (cytarabine and dexamethasone) with the PI3Kinhibitor Idelalisib was analysed on cell-biologic parameters in two acute pro-B lymphoblastic leukaemia (B-ALL) cell lines. In particular, for comparative characterisation of the molecular signatures induced by the combined and mono application, whole transcriptome sequencing was performed. Emphasis was placed on pathways and genes exclusively regulated by drug combinations. Results: Idelalisib + cytostatics combinations changed pathway activation for, e.g., "Retinoblastoma in cancer", "TGF-b signalling", "Cell cycle" and "DNA-damage response" to a greater extent than the two cytostatics alone. Analyses of the top-20 regulated genes revealed that both combinations induce characteristic gene expression changes. Conclusion: A specific set of genes was exclusively deregulated by the drug combinations, matching the combination-specific anti-proliferative cell-biologic effects. The addition of Idelalisib suggests minor synergistic effects which are rather to be classified as additive.

show abstract

Adult Acute Lymphoblastic Leukemia: A Genetic Overview and Application to Clinical Practice

Cited by 9 publications

References 43 publications

Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia

Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia

Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Contact Info

Product

Resources

About